SHINE 2Europe is a partner in the new project for personalized risk assessment for heart failure.

AI4HF is a new project funded by Horizon Europe, that brings together 16 partners from Europe, Peru and Tanzania, aiming to design, develop, evaluate and explore a reliable Artificial Intelligence solution for personalized assessment of the risk of heart failure. Leading the project is the Netherlands Heart Institute and Portugal is represented in the partnership by SHINE 2Europe.

AI4HF | Trustworthy Artificial Intelligence for Personalised Risk Assessment in Chronic Heart Failure was kicked-off in Utrecht, The Netherlands, on June 6th and 7th, where the group of researchers met to outline the first development strategies of the project.

SHINE 2Europe was represented by the researcher Miriam Cabrita and the company’s CEO, Carina Dantas, who says, on behalf of her team, that “we are excited to lead the works on Social Innovation within the project, because we have the opportunity to bring the voice of patients, health professionals, caregivers, policy makers, researchers, engineers in the field of Artificial Intelligence, among others. The goal is that, at the end, we can have a reliable tool with actual usability, that reaches people and can improve their quality of life.”

In Portugal, Heart Failure is one of the main, if not the main cause of mortality, and it is expected that between 500,000 and 600,000 people may suffer from this disease. There are still no updated data for 2023, since the last study was conducted more than 20 years ago, when the disease affected about 400,000 people. The Portuguese Society of Cardiology is this year preparing the new data that will be released next year, estimating that about 5000 people die each year due to Heart Failure in Portugal. Patients tend to devalue the symptoms of this disease that, being silent, makes them neglect their symptoms.

SHINE is happy to be involving all relevant actors in the development of this solution, which may become a real tool for the prevention of this pathology and decrease these numbers in the future.

For more info, please visit